Short answer
Guardant Health, Inc. (GH) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Guardant Health reported fiscal quarter results for quarter ended June 30, 2026.
Guardant Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Guardant Health reported fiscal quarter results for quarter ended June 30, 2026
- Full financial results furnished in Exhibit 99.1, requiring investor review for operating metrics and outlook
- Disclosure furnished under Regulation FD, limiting Section 18 liability and incorporation into other filings
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $335.0M, up 44%, led by Oncology $219.1M and Screening $52.9M
- Shield screening tests reached 66,000, up from 16,000, supporting rapid Screening adoption
- FDA approvals, ACS guideline inclusion, and UnitedHealth coverage strengthen Shield and Guardant360 commercialization
- 2026 revenue guidance raised to $1.34B-$1.36B, with Oncology growth near 30% and Shield volume of 270,000-285,000 tests
- Growth investment increases operating expense guidance to $1.08B-$1.10B and free-cash-flow burn to $195M-$205M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Guardant Health, Inc. 8-K filings
Get the next GH 8-K as it lands
Follow GH for push alerts, or ask the research agent what this filing means.